Summary
VAX4ASF aims to develop a state-of-the-art platform to produce highly effective and safe vaccines against ASFV targeted for both domestic pigs and wild boars. These vaccine candidates will be designed based on an innovative and robust vaccine platform that will guarantee immune protection against the different circulating ASFV variants in Europe, while avoiding the safety concerns arisen with the use of traditional live attenuated vaccine platforms. Vaccine candidates will effectively induce innate immune response with the adequate adaptive immunity. Moreover, the immunity induced will allow discrimination between vaccinated and infected animals, which will be monitored by complementary DIVA tests developed under the scope of the project. Given the complexity of ASFV genome and the still incomplete knowledge of the mechanisms involved in immune response to ASFV, VAX4ASF aims to further understand the molecular mechanisms of the virus and how it interacts with the host. The developed platform can be used to introduce new mutations based in this new generated knowledge which will allow to improve the efficacy and cross-protection of the vaccine prototypes.
VAX4ASF will provide new virus epidemiology models and control strategies using different mathematical models, leading to a better understanding of the ASFV transmission at the wild-domestic interface. In this way, innovative policies and strategies for ASFV control and management will be generated to ensure an outstanding impact through the continuous involvement of key stakeholders as project partners (farmers, wild board managers, veterinaries, hunters, policy makers...), leading to a profound effect in animal health and worldwide economy. The project relies on a solid collaboration trajectory between leading developers of innovative Animal Health vaccines and the highest experts in ASF field at international level, including partners from Europe, USA, and Kenya for the achievement of this challenge.
VAX4ASF will provide new virus epidemiology models and control strategies using different mathematical models, leading to a better understanding of the ASFV transmission at the wild-domestic interface. In this way, innovative policies and strategies for ASFV control and management will be generated to ensure an outstanding impact through the continuous involvement of key stakeholders as project partners (farmers, wild board managers, veterinaries, hunters, policy makers...), leading to a profound effect in animal health and worldwide economy. The project relies on a solid collaboration trajectory between leading developers of innovative Animal Health vaccines and the highest experts in ASF field at international level, including partners from Europe, USA, and Kenya for the achievement of this challenge.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101136439 |
| Start date: | 01-01-2024 |
| End date: | 31-12-2027 |
| Total budget - Public funding: | 5 234 950,00 Euro - 5 234 950,00 Euro |
Cordis data
Original description
VAX4ASF aims to develop a state-of-the-art platform to produce highly effective and safe vaccines against ASFV targeted for both domestic pigs and wild boars. These vaccine candidates will be designed based on an innovative and robust vaccine platform that will guarantee immune protection against the different circulating ASFV variants in Europe, while avoiding the safety concerns arisen with the use of traditional live attenuated vaccine platforms. Vaccine candidates will effectively induce innate immune response with the adequate adaptive immunity. Moreover, the immunity induced will allow discrimination between vaccinated and infected animals, which will be monitored by complementary DIVA tests developed under the scope of the project. Given the complexity of ASFV genome and the still incomplete knowledge of the mechanisms involved in immune response to ASFV, VAX4ASF aims to further understand the molecular mechanisms of the virus and how it interacts with the host. The developed platform can be used to introduce new mutations based in this new generated knowledge which will allow to improve the efficacy and cross-protection of the vaccine prototypes.VAX4ASF will provide new virus epidemiology models and control strategies using different mathematical models, leading to a better understanding of the ASFV transmission at the wild-domestic interface. In this way, innovative policies and strategies for ASFV control and management will be generated to ensure an outstanding impact through the continuous involvement of key stakeholders as project partners (farmers, wild board managers, veterinaries, hunters, policy makers...), leading to a profound effect in animal health and worldwide economy. The project relies on a solid collaboration trajectory between leading developers of innovative Animal Health vaccines and the highest experts in ASF field at international level, including partners from Europe, USA, and Kenya for the achievement of this challenge.
Status
SIGNEDCall topic
HORIZON-CL6-2023-FARM2FORK-01-5Update Date
12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| LABORATORIOS HIPRA SA (Coördinator)
-
| AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
-
| ASOCIACION INTERPROFESIONAL PORCINO DE CAPA BLANCA
-
| ASOCIACION-NACIONAL DE PRODUCTORESDE GANADO PORCINO
-
| HIPRA SCIENTIFIC SL
-
| HIPRA SOCIEDAD ANONIMA
-
| IN3DIAGNOSTIC S.R.L.
-
| International Livestock Research Institute
-
| KANSAS STATE UNIVERSITY
-
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
-
| MAGYAR AGRAR- ES ELETTUDOMANYI EGYETEM
-
| PANSTWOWY INSTYTUT WETERYNARYJNY - PANSTWOWY INSTYTUT BADAWCZY
-
| PROPHYL ALLATEGESZSEGUGYI DIAGNOSZTIKAI KUTATO ES SZOLGALTATO KFT
-
| SABIOTEC SPIN-OFF SL
-
| STATENS VETERINAERMEDICINSKA ANSTALT